Covidien International Finance prices $1.5 billion Senior Notes offering

NewsGuard 100/100 Score

Covidien plc (NYSE: COV) today announced that its wholly-owned subsidiary, Covidien International Finance S.A. (CIFSA), priced an offering of $500 million aggregate principal amount of 1.875% senior notes due 2013, $400 million aggregate principal amount of 2.80% senior notes due 2015 and $600 million aggregate principal amount of 4.20% senior notes due 2020. The offering is expected to close on June 28, 2010.

The notes will be CIFSA's senior unsecured obligations and will rank equally in right of payment with all of its existing and future senior debt, and senior to any subordinated indebtedness that CIFSA may incur. These notes are fully and unconditionally guaranteed on a senior unsecured basis by Covidien plc and its subsidiary, Covidien Ltd.

Covidien intends to use the net proceeds of this offering to finance a portion of the acquisition of ev3, Inc., which is expected to close by the end of July 2010. If the ev3 acquisition does not close prior to 5:00 p.m. (New York City time) on December 31, 2010, or if Covidien terminates the merger agreement or abandons the ev3 acquisition before that time, then CIFSA has agreed to redeem all of the notes at a redemption price equal to 101% of the aggregate principal amount of the notes (plus accrued and unpaid interest). The proceeds from the offering will be held in escrow pending release as applicable for the ev3 acquisition or the redemption described above.

Morgan Stanley & Co. Incorporated, Barclays Capital Inc. and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. The notes were offered pursuant to a shelf registration statement on Form S-3, which became automatically effective upon filing with the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering may be obtained by calling Morgan Stanley & Co. Incorporated at 1-866-718-1649, Barclays Capital Inc. at 1-888-603-5847 or Goldman, Sachs & Co. at 1-866-471-2526, by mailing the Prospectus Department, 200 West Street, New York, NY 10282, by sending a facsimile to 212-902-9316 or by emailing to [email protected].

Posted in:

Tags:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.